{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:45:50Z","timestamp":1758361550466,"version":"3.44.0"},"reference-count":25,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,9,19]]},"DOI":"10.1248\/bpb.b25-00371","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T22:08:26Z","timestamp":1758233306000},"page":"1399-1403","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of Pharmacists\u2019 Recommendations for Dental Examinations for Prevention of Medication-Related Osteonecrosis of the Jaw"],"prefix":"10.1248","volume":"48","author":[{"given":"Shinichi","family":"Watanabe","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmaceutical Sciences, Matsuyama University, 4\u20132 Bunkyo-cho, Matsuyama, Ehime 790\u20138578, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satomi","family":"Sumikawa","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Ehime University Hospital, 454 Shitsukawa, Toon, Ehime 791\u20130295, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Ebisuya Pharmacy Shitsukawa, 171 Shitsukawa, Toon, Ehime 791\u20130204, Japan"},{"name":"Ehime Pharmaceutical Association, 7\u20136\u20139 Sanban-cho, Matsuyama, Ehime 790\u20130003, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaaki","family":"Yano","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Ehime University Hospital, 454 Shitsukawa, Toon, Ehime 791\u20130295, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukiro","family":"Kurokawa","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Ehime University Hospital, 454 Shitsukawa, Toon, Ehime 791\u20130295, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriaki","family":"Hidaka","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Ehime University Hospital, 454 Shitsukawa, Toon, Ehime 791\u20130295, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Hino","sequence":"additional","affiliation":[{"name":"Department of Oral and Maxillofacial Surgery, Ehime University Graduate School of Medicine, 454 Shitsukawa, Toon, Ehime 791\u20130295, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takumi","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmaceutical Sciences, Matsuyama University, 4\u20132 Bunkyo-cho, Matsuyama, Ehime 790\u20138578, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mamoru","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Division of Pharmacy, Ehime University Hospital, 454 Shitsukawa, Toon, Ehime 791\u20130295, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. <i>J. Oral Maxillofac. Surg.<\/i>, <b>61<\/b>, 1115\u20131117 (2003).","DOI":"10.1016\/S0278-2391(03)00720-1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. <i>J. Oral Maxillofac. Surg.<\/i>, <b>62<\/b>, 527\u2013534 (2004).","DOI":"10.1016\/j.joms.2004.02.004"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Ishimaru M, Ono S, Morita K, Matsui H, Hagiwara Y, Yasunaga H. Prevalence, incidence rate, and risk factors of medication-related osteonecrosis of the jaw in patients with osteoporosis and cancer: a nationwide population-based study in Japan. <i>J. Oral Maxillofac. Surg.<\/i>, <b>80<\/b>, 714\u2013727 (2022).","DOI":"10.1016\/j.joms.2021.12.007"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, Diel IJ, Takahashi S, Shore N, Henry DH, Barrios CH, Facon T, Senecal F, Fizazi K, Zhou L, Daniels A, Carri\u00e8re P, Dansey R. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. <i>Ann. Oncol.<\/i>, <b>23<\/b>, 1341\u20131347 (2012).","DOI":"10.1093\/annonc\/mdr435"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Boquete-Castro A, G\u00f3mez-Moreno G, Calvo-Guirado JL, Aguilar-Salvatierra A, Delgado-Ruiz RA. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. <i>Clin. Oral Implants Res.<\/i>, <b>27<\/b>, 367\u2013375 (2016).","DOI":"10.1111\/clr.12556"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Maluf G, Caldas RJ, Fregnani ER, da Silva Santos PS. A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants. <i>Int. J. Implant Dent.<\/i>, <b>5<\/b>, 34 (2019).","DOI":"10.1186\/s40729-019-0188-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Kim HY. Review and update of the risk factors and prevention of antiresorptive-related osteonecrosis of the jaw. <i>Endocrinol. Metab. (Seoul)<\/i>, <b>36<\/b>, 917\u2013927 (2021).","DOI":"10.3803\/EnM.2021.1170"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Hallmer F, Andersson G, G\u00f6trick B, Warfvinge G, Anderud J, Bj\u00f8rnland T. Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw-a 4-year prospective study. <i>Oral Surg. Oral Med. Oral Pathol. Oral Radiol.<\/i>, <b>126<\/b>, 477\u2013485 (2018).","DOI":"10.1016\/j.oooo.2018.08.015"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Khan AA, Morrison A, Hanley DA, <i>et al<\/i>. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. <i>J. Bone Miner. Res.<\/i>, <b>30<\/b>, 3\u201323 (2015).","DOI":"10.1002\/jbmr.2524"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Nicolatou-Galitis O, Schi\u00f8dt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, Niepel D, Van den Wyngaert T. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. <i>Oral Surg. Oral Med. Oral Pathol. Oral Radiol.<\/i>, <b>127<\/b>, 117\u2013135 (2019).","DOI":"10.1016\/j.oooo.2018.09.008"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Brunner C, Arvandi M, Marth C, <i>et al<\/i>. Incidence of medication-related osteonecrosis of the jaw in patients with breast cancer during a 20-year follow-up: a population-based multicenter retrospective study. <i>J. Clin. Oncol.<\/i>, <b>43<\/b>, 180\u2013188 (2025).","DOI":"10.1200\/JCO.24.00171"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D. American Association of Oral and Maxillofacial Surgeons\u2019 position paper on medication-related osteonecrosis of the jaws-2022 update. <i>J. Oral Maxillofac. Surg.<\/i>, <b>80<\/b>, 920\u2013943 (2022).","DOI":"10.1016\/j.joms.2022.02.008"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Anastasilakis AD, Pepe J, Napoli N, Palermo A, Magopoulos C, Khan AA, Zillikens MC, Body JJ. Osteonecrosis of the jaw and antiresorptive agents in benign and malignant diseases: a critical review organized by the ECTS. <i>J. Clin. Endocrinol. Metab.<\/i>, <b>107<\/b>, 1441\u20131460 (2022).","DOI":"10.1210\/clinem\/dgab888"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Vandone AM, Donadio M, Mozzati M, Ardine M, Polimeni MA, Beatrice S, Ciuffreda L, Scoletta M. Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: a single-center clinical experience. <i>Ann. Oncol.<\/i>, <b>23<\/b>, 193\u2013200 (2012).","DOI":"10.1093\/annonc\/mdr039"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Troeltzsch M, Cagna D, St\u00e4hler P, Probst F, Kaeppler G, Troeltzsch M, Ehrenfeld M, Otto S. Clinical features of peri-implant medication-related osteonecrosis of the jaw: is there an association to peri-implantitis? <i>J. Craniomaxillofac. Surg.<\/i>, <b>44<\/b>, 1945\u20131951 (2016).","DOI":"10.1016\/j.jcms.2016.09.018"},{"key":"16","unstructured":"16) The Japanese Ministry of Health, Labour and Welfare\u2019s Manual for Responding to Serious Side Effects of Disease. \u201cMedication-related osteonecrosis of the jaw and osteomyelitis of the jaw.\u201d: &lt;https:\/\/www.pmda.go.jp\/files\/000274601.pdf&gt;, accessed 15 July, 2025."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Gonz\u00e1lez-Quevedo D, P\u00e9rez-Del-R\u00edo V, Moriel-Garceso D, Fern\u00e1ndez-Arroyabe N, Garc\u00eda-Mel\u00e9ndez G, Monta\u00f1ez-Ruiz M, Bravo-Bardaj\u00ed M, Garc\u00eda-de-Quevedo D, Tamimi I. A 2-year follow-up of a novel Fracture Liaison Service: can we reduce the mortality in elderly hip fracture patients? A prospective cohort study. <i>Osteoporos. Int.<\/i>, <b>33<\/b>, 1695\u20131702 (2022).","DOI":"10.1007\/s00198-022-06298-x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Wu CH, Li CC, Hsu YH, Liang FW, Chang YF, Hwang JS. Comparisons between different anti-osteoporosis medications on postfracture mortality: a population-based study. <i>J. Clin. Endocrinol. Metab.<\/i>, <b>108<\/b>, 827\u2013833 (2023).","DOI":"10.1210\/clinem\/dgac636"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Aguiar Bujanda D, Bohn Sarmiento U, Cabrera Su\u00e1rez MA, Aguiar Morales J. Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving Zoledronic acid for bone metastasis. <i>Ann. Oncol.<\/i>, <b>18<\/b>, 556\u2013560 (2007).","DOI":"10.1093\/annonc\/mdl408"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Brufsky AM, Sereika SM, Mathew A, Tomifumi O, Singh V, Rosenzweig M. Long-term treatment with intravenous bisphosphonates in metastatic breast cancer: a retrospective study. <i>Breast J.<\/i>, <b>19<\/b>, 504\u2013511 (2013).","DOI":"10.1111\/tbj.12152"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Fung P, Bedogni G, Bedogni A, <i>et al<\/i>. Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study. <i>Oral Dis.<\/i>, <b>23<\/b>, 477\u2013483 (2017).","DOI":"10.1111\/odi.12632"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Alblazi K, Nabil S, Tumian NR, Yunus SSM, Ramli R. Potential role of comprehensive dental care in preventing medication related osteonecrosis of the jaw (MRONJ): a single centre study. <i>BMC Oral Health<\/i>, <b>24<\/b>, 1291 (2024).","DOI":"10.1186\/s12903-024-05081-0"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) St\u00f6hr J, Barbaresko J, Neuenschwander M, Schlesinger S. Bidirectional association between periodontal disease and diabetes mellitus: a systematic review and meta-analysis of cohort studies. <i>Sci. Rep.<\/i>, <b>11<\/b>, 13686 (2021).","DOI":"10.1038\/s41598-021-93062-6"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Kim EH, Nam S, Park CH, Kim Y, Lee M, Ahn JB, Shin SJ, Park YR, Jung HI, Kim B-I, Jung I, Kim HS. Periodontal disease and cancer risk: a nationwide population-based cohort study. <i>Front. Oncol.<\/i>, <b>12<\/b>, 901098 (2022).","DOI":"10.3389\/fonc.2022.901098"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Gupta A, Pipe SG, Towheed T, Anastassiades T. Is rheumatoid arthritis a risk factor for fractures: a systematic review of observational studies. <i>Curr. Rheumatol. Rev.<\/i>, <b>16<\/b>, 29\u201337 (2020).","DOI":"10.2174\/1573397115666190723160312"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/9\/48_b25-00371\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T04:01:59Z","timestamp":1758340919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/9\/48_b25-00371\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00371","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"type":"print","value":"0918-6158"},{"type":"electronic","value":"1347-5215"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"article-number":"b25-00371"}}